SCHEMBL6356063

SCHEMBL6356063

COc1ccc(C(=O)N(CC(=O)c2ccccc2)C(C(N)=O)C(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
TRPM8 Q7Z2W7 2/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
HSD11B1 P28845 1/20 0.42
TSHR P16473 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRL1 P41146 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350477 0.90 L3MBTL1 (0.51) L3MBTL1NPC1RAB9AKDM4EHPGD
SCHEMBL6350864 0.90 TRPM8 (0.47) L3MBTL1KDM4EHPGDTRPM8CES1
SCHEMBL6359179 0.90 TRPM8 (0.47) L3MBTL1KDM4EHPGDTRPM8CES1
SCHEMBL6349745 0.88 TRPM8 (0.54) L3MBTL1NPC1RAB9ATRPM8CES2
SCHEMBL6358312 0.86 CTNNB1 (0.45) NPC1RAB9AHPGDTSHRKMT2A
SCHEMBL6359454 0.83 CYP3A4 (0.47) L3MBTL1NPC1RAB9AKDM4EHPGD
SCHEMBL6351225 0.83 CYP3A4 (0.47) L3MBTL1NPC1RAB9AKDM4EHPGD
SCHEMBL6359355 0.83 TP53 (0.42) L3MBTL1TRPM8CYP1A2NPSR1TSHR
SCHEMBL6350699 0.81 ALDH1A1 (0.47) L3MBTL1NPC1RAB9ACES2CES1
SCHEMBL6350601 0.81 KMT2A (0.42) L3MBTL1NPC1RAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 L3MBTL1 3961/4885NPC1 2985/4885RAB9A 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.